What’s the current market cap for Lantheus stock?

Lantheus (LNTH) has a market cap of $6.5B as of May 27, 2026.

What is the P/E ratio for Lantheus stock?

The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 24.05 as of May 27, 2026.

Does Lantheus stock pay dividends?

No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of May 27, 2026.

When is the next Lantheus dividend payment date?

Lantheus (LNTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Lantheus?

Lantheus (LNTH) has a beta rating of -0.08. This means that it has an inverse relation to market volatility.

Buy Lantheus stock | $LNTH Share Price

About Lantheus

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

Ticker

$LNTH

Sector

Health

Primary listing

NASDAQ

Employees

1,193

Headquarters

Bedford, United States

Website

www.lantheus.com

Lantheus Metrics

BasicAdvanced

$6.5bn

24.05

$4.16

-0.08

-

What the Analysts think about Lantheus

Analyst ratings (Buy, Hold, Sell) for Lantheus stock.

Bulls say / Bears say

Lantheus has agreed to buy Life Molecular Imaging for $350 million upfront, with possible earn-outs up to $400 million. This deal is projected to be accretive to adjusted EPS within 12 months and will expand its Alzheimer’s radiodiagnostic portfolio.

The company introduced a $400 million stock buyback program in Q2, reflecting management’s confidence in long-term free cash flow and its commitment to capital returns.

The FDA has accepted the NDA for a new formulation of its piflufolastat F18 PSMA PET imaging agent and set a PDUFA date of March 6, 2026, which could improve production efficiency, strengthen supply, and support maintaining transitional pass-through payment status.

Q2 revenue declined 4.1% year-over-year to $378 million, falling short of the $389.1 million analysts expected, indicating weaker demand in core imaging diagnostics.

Adjusted EPS for Q2 came in at $1.57, missing the consensus estimate of $1.67, underscoring margin pressure from higher costs.

Rising competition in the PSMA PET market hurt PYLARIFY sales, affecting performance in the flagship radiopharmaceutical oncology segment.

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

Lantheus Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Lantheus Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Lantheus News

AllArticlesVideos

Lantheus weighs potential $7 billion sale, Bloomberg News reports

Reuters·5 days ago

Lantheus Q1 Earnings Call Highlights

MarketBeat·3 weeks ago

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

Business Wire·3 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.